On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved aducanumab, a therapy for the treatment of Alzeihmer’s disease sponsored by Biogen and set to be commercialized under the brand name Aduhelm. Aduhelm was the first treatment for Alzeihmer’s approved by the FDA since 2003....

This Article makes the case that pharmaceutical companies, along with other powerful corporate actors in the pharmaceutical industry, are in effect designing their own markets, often at the expense of, rather than in pursuit of, public health. The influence exerted by these corporate actors...

Our healthcare system is broken. Despite spending far more on healthcare per capita than any other country, health outcomes in the U.S. are relatively poor. There is a pervasive disconnect within the healthcare system between private incentives to develop and provide healthcare products and...

As costs rise and concerns grow about the pace of pharmaceutical innovation, both federal agencies and industry participants have turned to new forms of collaboration to increase the efficiency and effectiveness of biomedical research. Industry participants, many of them competitors, come...

Public-private partnerships offer a promising alternative paradigm for pharmaceutical innovation in complex disease areas where there are both strong commercial interests and significant public need. They have the potential to reduce the tremendous waste associated with duplicative unsuccessful...

Patent law, created in response to a constitutional mandate to en-courage innovation, may be discouraging important forms of cooperative innovation. Advances in technology have enabled new ways of pooling knowledge and computational capabilities, facilitating cooperation among many participants...

[enter Abstract Body]In light of the significant cost of legal change in an economic climate that can little afford wasted expense it has become imperative to re-examine costs associated with alternative avenues for achieving legal reform. This is particularly true in areas such as patent law...

There is a growing belief both within and outside of Congress that the system of university technology transfer upon which U.S. innovation relies is broken. Too many good ideas, ranging from promising drug candidates to revolutionary clean energy technologies, either fail to reach the public or...